KDR and glioblastoma: Additionally, altiratinib, a Met/TIE-2/VEGFR2 inhibitor, in combination with bevacizumab has been reported to significantly decrease tumor volume, invasiveness, microvessel density, expression of mesenchymal marker, and TIE-2 expressing monocyte infiltration in glioblastoma xenograft mouse models as compared to bevacizumab monotherapy [58].